Lipanthyl nt 145mg Abbott supports blood cholesterol and progression of diabetic retinopathy (3 blisters x 10 tablets)

Dosage form Box of 3 blisters x 10 tablets
Specifications Fenofibrat

Ingredient

Thành phần cho 1 viên

Composition information	Content
Fenofibrat	145mg

Uses

Indications

lipanthyl NT 145mg is indicated to support diet in treatment:

Hyper cholesterol . Diabetes retinal diabetes. Lipanthyl NT 145mg does not replace the control of blood pressure, blood sugar and blood lipids in reducing the progression of diabetic retinopathy.

Code ATC: C10 AB 05.

Fenofibrat is a derivative of fibric acid, which has the effect of changing blood lipid levels in people intermediaries through the activation of the alpha peroxisome hypertension (PPAR - α). Through the activation of PPAR - α, Fenofibrat increases lipid decomposition and the exit of plasma -rich sub -fertilizers from plasma by activating lipoprotein lipase and reducing the production of apoprotein CII. Activation of PPAR - α also increases the synthesis of apoprotein Al and All.

In addition, through the synthesis and catabolic changes of VLDL components, Fenofibrat increases LDL clearance and low density LDL reduction. LDL's concentration is often increasing in risks (arteriosclerosis caused by blood lipids).

Periodic cholesterol condensation: Patients with high fibrinogen levels are treated with fenofibrat that this parameter is significantly reduced as well as high LP (A) people. The physical expression for inflammation such as C Reactive Protein also decreases when treated with fenofibrat.

The effect of increasing urinary uric acid Export of fenofibrat, which leads to a reduction in uric acid about 25%, is also a very beneficial supportive effect in patients with lipid disorders accompanied by hyperuricemia.

Fenofibrat has anti -platelet aggregation effects on animal and clinical trials, reducing platelet aggregation created by ADP, arachidonic acid and epinephrine. Accord research also shows that the combination of fenofibrat with simvastatin reduces diabetic retinopathy progression, reduces general protein, reduces microscopic protein compared to simvastatin.

In Field research, Fenofibrat reduces spending due to injury compared to the control group.

pharmacokinetic

absorption

Maximum concentration in plasma (cmax) reaches 2-4 hours after drinking. The concentration of drugs in blood stabilizes when treating continuously in all fish.

Lipanthyl film tablets NT 145mg regardless of the meal.

Distribution

Fenofibric acid is strongly linked to plasma albumin (> 99%).

Metabolism and elimination

After drinking, fenofibrat is quickly hydrolyzed through the catalyst of the esterase so that the metabolites are active as fenofibric acid. There is no metabolism through the liver microsom. This drug is mainly excreted in urine mainly in the form of fenofibric acid and glucuronid complex.

Selling waste time of fenofibric acid from plasma from about 20 hours.

Before taking Lipanthyl nt 145mg Abbott supports blood cholesterol and progression of diabetic retinopathy (3 blisters x 10 tablets)

How to use

Should swallow the tablet with a cup of water.

Lipanthyl NT 145mg, film covers can be taken at any time of the day, or not food.

Dosage

Adults

recommended dose is a 145mg fenofibrat tablet, taken once daily.

Patients with 200mg fenofibrat capsule (or 1 film tablet 160mg fenofibrat) can be switched to treatment with lipanthyl film tablets NT 145mg, 1 tablet daily without adjusting the dose.

Elderly patients

No dose adjustment for elderly patients without renal failure.

Patients with renal failure

Need to adjust the dose according to the clearinine clearance (CRCI): CrCl> 60ml/minute: use 1 tablet 145mg/day.

It is not recommended to use Fenofibrat 145mg when creatinine clearance is below 60ml/min.

Recommendation for dosage reduction for patients with renal impairment. For patients with medium renal impairment (CrCl from 30 to 60 ml/minute) and if there is a lower dosage available, start using 1 capsule 100mg or 67mg fenofibrat micro -type micro -form a day. If there is no low doses, do not recommend using fenofibate.

In patients with severe renal impairment (CrCl

Patients with liver failure

Lipanthyl NT 145mg is not recommended for patients with liver failure because there is no enough data.

Children

Contraindicated dose of this 145mg dosage for children.

Treatment process

Coordinate with diet, this pharmaceutical is used to treat symptoms, according to the prolonged process and regular monitoring.

For good treatment, medical monitoring is needed.

Note: The above dose is for reference only. Specific dosage depends on the condition and level of progression of the disease. For a suitable dose, you need to consult a doctor or medical specialist.

What to do when overdose? Fenofibrat is not excluded when dialysis.

What to do when you forget a dose? However, if close to the next dose, skip the forgotten dose and take the next dose at the time as planned. Note that it should not be used double the prescribed dose.

Side Effects

When using Lipanthyl NT 145mg, you may experience unwanted effects (ADR).

Very common, 1/10

Testing indicators: Increased bloodsteine concentration.

Common, 1/100

Gastrointestinal disorders: Symptoms of function and stomach - bowel (abdominal pain, vomiting, nausea, diarrhea , flatulence).

Liver disorders: Moderate increase serum levels.

Uncommon, 1/1000

Nervous system disorders: headache.

Vascular disorders: blood vessels (pulmonary embolism, deep vein thrombosis). digestive disorders: pancreatitis .

Liver disorders: gallstones .

Skin and subcutaneous tissue disorders: Increased skin sensitivity (for example, rash, itching, urticaria).

musculoskeletal disorders, connective tissue and bone: muscle pain spread, muscle inflammation, muscle contraction, muscle weakness.

Chest disorders and reproductive systems: Sexual dysfunction.

Testing indicators: hypernestia blood.

Rare, 1/10000

Blood disorders and lymphatic systems: Hemoglobin and leukocytes.

Immune system disorders: allergies.

Skin and subcutaneous tissue disorders: Hair loss , light -sensitive reactions.

Testing indicators: Hyper urea.

Very rare, ADR, 1/10000

Hepatitis: Hepatitis.

(When encountering side effects of the drug, it is necessary to stop using and notify the doctor or go to the nearest medical facility for timely treatment.)

Warnings

Before using the drug you need to read the instructions carefully and refer to the information below.

Contraindicated

Do not use lipanthyl nt 145mg in the following cases:

Hepatic failure (including biliary cirrhosis).

History of hypersensitivity reactions to light or light poisoning during treatment with fibrat or ketoprofen.

Diseases in the gallbladder.

Used for breastfeeding women.

No prescription lipanthyl nt 145mg, film bag tablets for patients with allergies to peanuts or peanut oil, lecithin of soybean or related preparations, due to the risk of hypersensitivity reactions.

Caution when using

In cases of secondary cholesterol hyperplasia such as type 2 diabetes uncontrolled, thyroid failure, kidney syndrome, blood protein disorders, obstructive liver disease, alcoholic, should be treated satisfactorily before using Fenofibrat therapy.

Monitoring treatment response by determining serum lipid value (total cholesterol, LDL - cholesterol, triglyceride), if fully responded, is not achieved after a few months (for example, 3 months) should consider additional or use other alternative therapies.

For patients with high blood fat using estrogen or contraceptives containing estrogen, it is clear that increased blood fat is primary or secondary (with increased blood fat due to drinking.

Liver function: Like other lipid medications, there has been reports on increased transaminase levels in some patients. Most of these cases only increase fleeting, few and almost asymptomatic. It is recommended to monitor the concentration of transaminase periodically every 3 months in the first 12 months of treatment and then periodically check.

Pancreatitis: There have been cases of pancreatitis recorded in patients using fenofibrat.

Mechanical: There has been a report on muscle toxicity, including rare Myoglobulin when using fibrats and other lipid medications. Must consider the benefits and risks when treating with fenofibrat for these patients.

It is necessary to think about toxicity with muscle when the patient appears muscle pain, muscle inflammation with muscle seizures of pain, cramps and muscle weakness, or increasing signs on CPK (concentration of more than 5 times normal level). Stop treatment with fenofibrat in these cases.

Increased risk of muscle toxicity when the drug is used simultaneously with other fibrats or HMG inhibitors - CoA Reductase or other fenofibrat drugs for patients without a history of muscle disease but with severe hyperplasher disorders with high cardiovascular disease.

Kidney function: Stop treatment in case of increased creatinine concentration above 50% of ULN (the upper limit of normal). Consider measuring creatinine in the first 3 months of treatment.

excipients

This drug contains lactose, so patients have rare genetic problems in tolerance of galactose, lapp lactase enzyme deficiency or Glucose - Galactose should not use this drug.

This drug contains sucrose, so patients have rare genetic problems in non -tolerance fructose, malposine - galactose or Sucrase - Isomaltase deficiency should not use this drug.

If the patient is not tolerated with some types of sugar, ask your doctor before taking this medication

serum creatinine: Increased serum creatinine levels have been reported in patients using fenofibrat. Creatinine concentration will return to normal when stop using fenofibrat.

Causes bile stasis: may increase the secretion of cholesterol into bile, leading to gallstones. If there is a suspected gallstones, check the gallbladder. Fenofibrat should be stopped if found gallstones.

Venous thrombosis: may appear deep veins, pulmonary embolism.

Change of blood: There is a mitigation of hemoglobin, hematocrit and leukocytes. Need to check the number of red blood cells and white blood cells in the first 12 months of treatment.

Hypersensitive reactions: Acute hypersensitivity reactions such as Stevens - Johnson syndrome, poisoned epidermal necrosis need to be hospitalized and steroid treatment, urticaria and rash.

The effect of reducing HDL - C: There is a report after circulation and clinical trial report of serious decline in HDL - C concentration (the smallest is 2mg/dl) occurs in patients with diabetes and no diabetes started to treat Fibrat. This decline appears within 2 weeks to the years after fibrat treatment. The concentration of HDL - C is maintained at a low level until stopping with fibrat, responding to the stop use of Fibrat occurs quickly and stable. HDL - C concentration should be checked for the first few months after starting fibrat treatment. If you see a significant reduction in HDL - C levels, Fibrat treatment should be discontinued and monitor HDL - C levels until normal returns and should not use Fibrat.

Use the same anticoagulant drugs: Caution should be used when taking anticoagulant drugs with fenofibrat because of the ability to anticoagulant drugs that prolong prothrombin/international standard ratio (PT/INR). To prevent bleeding complications, regularly check PT/INR and need to adjust the dose of anticoagulants until PT/INR is stable (see drug interaction).

The ability to drive and operate machinery

without or has a significant impact on the ability to drive and operate machinery.

Pregnancy

There is no enough data to use fenofibrat for pregnant women.

Should only use lipanthyl 145mg during pregnancy when thoroughly evaluating the benefits/risk.

Breastfeeding period

Contraindications.

Medicinal interaction

Antaginalned oral medication: It is not recommended to combine fenofibrat with anticoagulant oral medications. Fenofibrat increases the effects of anticoagulant oral medications and may increase the risk of bleeding.

Cyclosporin: Some cases of reversible renal function have been recorded.

HMG inhibitors - COA Reductase and other fenofibrats: increased the risk of muscle poisoning.

Cytochrome P450 enzymes: Strict monitoring patients using simultaneously fenofibrat and metabolic drugs through CYP2C19, CYP2A6, especially CYP2C9, with accurate treatment index, recommend the dose adjustment of these drugs if necessary.

Glitazone: Some reversible decreases with HDL - cholesterol recovery have been recorded when used simultaneously Fenofibrat and Glitazon. However, it is recommended to monitor HDL - cholesterol if using this combination and stop treatment if HDL - cholesterol is too low.

Bile acid -mounted resin: Because the bile acid -mounted resin can be attached to other drugs when used simultaneously, patients should take fenofibrat at least 1 hour or 4 to 6 hours after using the bile acid -mounted resin to avoid obstructing absorption.

Colchicin: Cases of muscle disease, including muscle pepper, have been reported when using fenofibrat simultaneously with colchicine and should be cautious when prescribing fenofibrat with colchicine.

Storage

Keep the drug in the original packaging. Do not store drugs above 30 ° C.

Other drugs

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.